Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 42

1.

The LKB1-AMPK pathway: metabolism and growth control in tumour suppression.

Shackelford DB, Shaw RJ.

Nat Rev Cancer. 2009 Aug;9(8):563-75. doi: 10.1038/nrc2676.

2.

mTOR and HIF-1alpha-mediated tumor metabolism in an LKB1 mouse model of Peutz-Jeghers syndrome.

Shackelford DB, Vasquez DS, Corbeil J, Wu S, Leblanc M, Wu CL, Vera DR, Shaw RJ.

Proc Natl Acad Sci U S A. 2009 Jul 7;106(27):11137-42. doi: 10.1073/pnas.0900465106. Epub 2009 Jun 18.

3.

Somatic LKB1 mutations promote cervical cancer progression.

Wingo SN, Gallardo TD, Akbay EA, Liang MC, Contreras CM, Boren T, Shimamura T, Miller DS, Sharpless NE, Bardeesy N, Kwiatkowski DJ, Schorge JO, Wong KK, Castrillon DH.

PLoS One. 2009;4(4):e5137. doi: 10.1371/journal.pone.0005137. Epub 2009 Apr 2.

4.

Targeting the mTOR signaling network for cancer therapy.

Meric-Bernstam F, Gonzalez-Angulo AM.

J Clin Oncol. 2009 May 1;27(13):2278-87. doi: 10.1200/JCO.2008.20.0766. Epub 2009 Mar 30. Review.

5.

Somatic alterations of the serine/threonine kinase LKB1 gene in squamous cell (SCC) and large cell (LCC) lung carcinoma.

Strazisar M, Mlakar V, Rott T, Glavac D.

Cancer Invest. 2009 May;27(4):407-16. doi: 10.1080/07357900802427919.

PMID:
19229701
6.

Chemopreventive efficacy of rapamycin on Peutz-Jeghers syndrome in a mouse model.

Wei C, Amos CI, Zhang N, Zhu J, Wang X, Frazier ML.

Cancer Lett. 2009 May 18;277(2):149-54. doi: 10.1016/j.canlet.2008.11.036. Epub 2009 Jan 14.

7.

LKB1; linking cell structure and tumor suppression.

Hezel AF, Bardeesy N.

Oncogene. 2008 Nov 24;27(55):6908-19. doi: 10.1038/onc.2008.342. Review.

PMID:
19029933
8.

beta-catenin mediates glandular formation and dysregulation of beta-catenin induces hyperplasia formation in the murine uterus.

Jeong JW, Lee HS, Franco HL, Broaddus RR, Taketo MM, Tsai SY, Lydon JP, DeMayo FJ.

Oncogene. 2009 Jan 8;28(1):31-40. doi: 10.1038/onc.2008.363. Epub 2008 Sep 22.

9.

Conditional loss of uterine Pten unfailingly and rapidly induces endometrial cancer in mice.

Daikoku T, Hirota Y, Tranguch S, Joshi AR, DeMayo FJ, Lydon JP, Ellenson LH, Dey SK.

Cancer Res. 2008 Jul 15;68(14):5619-27. doi: 10.1158/0008-5472.CAN-08-1274.

10.

Differential roles of telomere attrition in type I and II endometrial carcinogenesis.

Akbay EA, Contreras CM, Perera SA, Sullivan JP, Broaddus RR, Schorge JO, Ashfaq R, Saboorian H, Wong KK, Castrillon DH.

Am J Pathol. 2008 Aug;173(2):536-44. doi: 10.2353/ajpath.2008.071179. Epub 2008 Jul 3.

11.

Loss of tuberous sclerosis complex-2 function and activation of mammalian target of rapamycin signaling in endometrial carcinoma.

Lu KH, Wu W, Dave B, Slomovitz BM, Burke TW, Munsell MF, Broaddus RR, Walker CL.

Clin Cancer Res. 2008 May 1;14(9):2543-50. doi: 10.1158/1078-0432.CCR-07-0321.

12.

High-throughput lung cancer cell line screening for genotype-correlated sensitivity to an EGFR kinase inhibitor.

McDermott U, Sharma SV, Settleman J.

Methods Enzymol. 2008;438:331-41. doi: 10.1016/S0076-6879(07)38023-3.

PMID:
18413259
13.

BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models.

Li D, Ambrogio L, Shimamura T, Kubo S, Takahashi M, Chirieac LR, Padera RF, Shapiro GI, Baum A, Himmelsbach F, Rettig WJ, Meyerson M, Solca F, Greulich H, Wong KK.

Oncogene. 2008 Aug 7;27(34):4702-11. doi: 10.1038/onc.2008.109. Epub 2008 Apr 14.

14.

Lkb1 deficiency causes prostate neoplasia in the mouse.

Pearson HB, McCarthy A, Collins CM, Ashworth A, Clarke AR.

Cancer Res. 2008 Apr 1;68(7):2223-32. doi: 10.1158/0008-5472.CAN-07-5169.

15.

Suppression of Peutz-Jeghers polyposis by targeting mammalian target of rapamycin signaling.

Wei C, Amos CI, Zhang N, Wang X, Rashid A, Walker CL, Behringer RR, Frazier ML.

Clin Cancer Res. 2008 Feb 15;14(4):1167-71. doi: 10.1158/1078-0432.CCR-07-4007.

16.

Loss of Lkb1 provokes highly invasive endometrial adenocarcinomas.

Contreras CM, Gurumurthy S, Haynie JM, Shirley LJ, Akbay EA, Wingo SN, Schorge JO, Broaddus RR, Wong KK, Bardeesy N, Castrillon DH.

Cancer Res. 2008 Feb 1;68(3):759-66. doi: 10.1158/0008-5472.CAN-07-5014.

17.

Pancreatic LKB1 deletion leads to acinar polarity defects and cystic neoplasms.

Hezel AF, Gurumurthy S, Granot Z, Swisa A, Chu GC, Bailey G, Dor Y, Bardeesy N, Depinho RA.

Mol Cell Biol. 2008 Apr;28(7):2414-25. doi: 10.1128/MCB.01621-07. Epub 2008 Jan 28.

18.

Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis.

Bissler JJ, McCormack FX, Young LR, Elwing JM, Chuck G, Leonard JM, Schmithorst VJ, Laor T, Brody AS, Bean J, Salisbury S, Franz DN.

N Engl J Med. 2008 Jan 10;358(2):140-51. doi: 10.1056/NEJMoa063564.

19.

LKB1 deficiency sensitizes mice to carcinogen-induced tumorigenesis.

Gurumurthy S, Hezel AF, Sahin E, Berger JH, Bosenberg MW, Bardeesy N.

Cancer Res. 2008 Jan 1;68(1):55-63. doi: 10.1158/0008-5472.CAN-07-3225. Erratum in: Cancer Res. 2008 Apr 1;68(7):2549. Sahin, Ergun [added].

20.

Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.

McDermott U, Sharma SV, Dowell L, Greninger P, Montagut C, Lamb J, Archibald H, Raudales R, Tam A, Lee D, Rothenberg SM, Supko JG, Sordella R, Ulkus LE, Iafrate AJ, Maheswaran S, Njauw CN, Tsao H, Drew L, Hanke JH, Ma XJ, Erlander MG, Gray NS, Haber DA, Settleman J.

Proc Natl Acad Sci U S A. 2007 Dec 11;104(50):19936-41. Epub 2007 Dec 6.

Supplemental Content

Support Center